natgillin/translations-raw huggingface dataset:
Der er også rapporteret om udslæt som en del af et overfølsomhedssyndrom, der er forbundet med et skiftende mønster af systemiske symptomer, herunder feber, lymfadenopati, ansigtsødem samt blodog leverabnormiteter (se pkt. 
Rash has also been reported as part of a hypersensitivity syndrome associated with a variable pattern of systemic symptoms including fever, lymphadenopathy, facial oedema and abnormalities of the blood and liver (see section 4.8).
• Risperidon, der anvendes til behandling af psykiske problemer 
• risperidone, used to treat mental health problems
Hjælpestof: Hver tablet indeholder 23,5 mg lactose. 
Excipient: Each tablet contains 23.5 mg lactose.
Startpakning med 21 eller 42 dispergible tabletter / tyggetabletter. 
Starter pack of 21 or 42 dispersible/chewable tablets.
200 mg/dag - normal måldosis til opnåelse af optimal respons (én gang dagligt eller fordelt på to doser) 
200 mg/day - usual target dose for optimal response (once a day or two divided doses)
25 mg/dag (én gang dagligt) 
25 mg/day (once a day)
- Høj initialdosis og overskridelse af den anbefalede dosisøgning af lamotrigin (se pkt. 
- high initial doses of lamotrigine and exceeding the recommended dose escalation of lamotrigine therapy (see section 4.2) - concomitant use of valproate (see section 4.2).
100 mg/dag - normal måldosis til opnåelse af optimal respons (én gang dagligt eller fordelt på to doser) 
100 mg/day - usual target dose for optimal response (once a day or two divided doses)
Pakninger med 30, 56 eller 100 tabletter. 
Packs of 30, 56 or 100 tablets.
100 mg/dag Oprethold denne dosis (100 mg/dag) 
100 mg/day Maintain this dose (100 mg/day)
trombocytopeni, pancytopeni, aplastisk anæmi, agranulocytose. 
haematological abnormalities including neutropenia, leucopenia, anaemia, thrombocytopenia, pancytopenia, aplastic anaemia, agranulocytosis.
Hvis det, på baggrund af klinisk behov, alligevel besluttes at behandle, se pkt. 
If, based on clinical need, a decision to treat is nevertheless taken, see sections 4.4, 5.1 and 5.2.
Bipolar sygdom 
Bipolar Disorder
Lamictal-tabletter (alle styrker) er kvadratiske med afrundede hjørner og lyse og gulligbrune i farven. 
What Lamictal tablets look like and contents of the pack Lamictal tablets (all strengths) are square with rounded corners, and pale, yellowish brown in colour.
Grækenland GlaxoSmithKline α.ε.β.ε 266 Kifissias Ave 
GlaxoSmithKline α.ε.β.ε 266 Kifissias Ave 152 32 Halandri Athens
Tabel 5: Voksne i alderen 18 år og derover - justering af den daglige lamotrigin-dosis efter tilføjelse af andre lægemidler ved behandling af bipolar sygdom 
Table 5: Adults aged 18 years and above - adjustment of lamotrigine daily dosing following the addition of other medicinal products in treatment of bipolar disorder There is no clinical experience in adjusting the lamotrigine daily dose following the addition of other medicinal products.
Det bør derfor overvejes at bruge antikonception uden en pillefri uge, som førstevalgsbehandling (for eksempel kontinuerlige hormonale kontraceptiva eller ikke-hormonale metoder; se pkt. 
Therefore, consideration should be given to using contraception without a pill-free week, as first-line therapy (for example, continuous hormonal contraceptives or non-hormonal methods; see sections 4.4 and 4.5).
Lamotrigin metaboliseres af enzymerne UDP-glukuronyltransferaser. 
UDP-glucuronyl transferases have been identified as the enzymes responsible for metabolism of lamotrigine.
Startpakning 21 dispergible tabletter / tyggetabletter, valproat tillægsbehandling Startpakning 42 dispergible tabletter / tyggetabletter, monoterapi 
Starter pack 21 dispersible/chewable tablets, valproate add-on therapy Starter pack 42 dispersible/chewable tablets, monotherapy
For at nå vedligeholdelsesdosis må doserne maksimalt øges med 50-100 mg hver eller hver anden uge, indtil den optimale respons er opnået Hos patienter, der tager lægemidler, hvor den farmakokinetiske interaktion med lamotrigin ikke kendes på nuværende tidspunkt (se pkt. 
To achieve maintenance, doses may be increased by maximum of 50 - 100 mg every one to two weeks until optimal response is achieved In patients taking medicinal products where the pharmacokinetic interaction with lamotrigine is currently not known (see section 4.5), the treatment regimen as recommended for lamotrigine with concurrent valproate should be used.
Somnolens, ataksi, svimmelhed, hovedpine. 
somnolence, ataxia, dizziness, headache.
Kvalme, opkastning. 
nausea, vomiting.
Lamictal 2 mg dispergible tabletter / tyggetabletter er runde. 
Lamictal 2 mg dispersible/chewable tablets are round.
Tabel 7: Resume af resultater fra forsøg, hvor effekten af lamotrigin til forebyggelse af stemningssvingninger hos patienter med bipolar affektiv sindslidelse af type I undersøges 'Andelen' af patienter, som er hændelsesfri efter 76 uger Forsøg SCAB2003 Bipolar affektiv sindslidelse af type I 
Table 7: Summary of results from studies investigating the efficacy of lamotrigine in the prevention of mood episodes in patients with bipolar I disorder
Pludselig seponering af Lamictal kan, som det også er tilfældet med andre antiepileptika, fremprovokere rebound-krampeanfald. 
As with other AEDs, abrupt withdrawal of Lamictal may provoke rebound seizures.
50 mg/dag (én gang dagligt) 
50 mg/day (once a day)
Efter administration af enkeltdoser faldt den påviselige clearance med 12 % fra 35 ml/min. 
After single doses apparent clearance decreased by 12% from 35 mL/min at age 20 to 31 mL/min at 70 years.
Voksne og unge på 13 år og derover - Tillægsbehandling eller monoterapi ved partielle anfald og generaliserede anfald, herunder tonisk-kloniske anfald. 
Adults and adolescents aged 13 years and above - Adjunctive or monotherapy treatment of partial seizures and generalised seizures, including tonic-clonic seizures.
Oprethold den måldosis, der er opnået ved dosisøgning (200 mg/dag, dosisinterval 100-400 mg/dag) 
Maintain target dose achieved in dose escalation (200 mg/day; dose range 100-400 mg/day)
SÅDAN OPBEVARER DU LAMICTAL 
HOW TO STORE LAMICTAL
Startpakning 42 tabletter, ikke-valproat tillægsbehandling 
Starter pack 42 tablets, non-valproate add-on therapy
Oprethold den måldosis, der er opnået ved dosisøgning (200 mg/dag fordelt på to doser) (dosisinterval 100-400 mg/dag) 
Maintain target dose achieved in dose escalation (200 mg/day; two divided doses) (dose range 100 - 400 mg/day)
For at nå vedligeholdelsesdosis må doserne maksimalt øges med 1,2 mg/kg hver eller hver anden uge, indtil den optimale respons er opnået, og vedligeholdelsesdosis må maksimalt være 400 mg/dag 
To achieve maintenance, doses may be increased by maximum of 1.2 mg/kg every one to two weeks until optimal response is achieved, with a maximum maintenance dose of 400 mg/day
Hovedpine. 
headache.
Lægemidler, der ikke signifikant hæmmer eller inducerer glukuronidering af lamotrigin 
Medicinal products that do not significantly inhibit or induce glucuronidation of lamotrigine
Børn og unge på 2 til 12 år - Tillægsbehandling af partielle anfald og generaliserede anfald, herunder tonisk-kloniske anfald og anfald ved Lennox-Gastaut syndrom. 
Children and adolescents aged 2 to 12 years - Adjunctive treatment of partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with Lennox-Gastaut syndrome.
(Starter pack 42 tabletter, ikke-valproat tillægsbehandling - kaldender pakning viser dagnumre): 1 2 3 4 5 6 7 (1 lomme) 
(Starter pack 42 tablets, non-valproate add-on therapy - calender pack showing day numbers): 1 2 3 4 5 6 7 (1 pocket)
Monoterapi med lamotrigin ELLER tillægsbehandling UDEN valproat og UDEN induktorer af lamotriginglukuronidering (se pkt. 
Monotherapy with lamotrigine OR adjunctive therapy WITHOUT valproate and WITHOUT inducers of lamotrigine glucuronidation (see section 4.5):
Lægemidler, der signifikant inducerer glukuronidering af lamotrigin 
Medicinal products that significantly induce glucuronidation of lamotrigine
Lamictal 200 mg tabletter er påtrykt 'GS SEE7' på den ene side og '200' på den anden side. 
Lamictal 200 mg tablets are marked ‘GSEE7' on one side and ‘200' on the other.
(Starpakning 21 tabletter, valproat tillægsbehandling - kaldender pakning viser dagnumre): 1 3 5 7 9 11 13 (en lomme) 
(Starter pack 21 tablets, valproate add-on therapy - calender pack showing day numbers): 1 3 5 7 9 11 13 (one pocket)
Fortæl det altid til lægen eller på apoteket, hvis du bruger anden medicin eller har brugt det for nylig. 
Tell your doctor or pharmacist if you're taking any other medicines, if you've taken any recently, or if you start taking new ones - these include herbal medicines or other medicines you bought without a prescription.
150 mg/dag 
150 mg/day
Lamictal indeholder: 
Do not take Lamictal:
“Voksne og børn over 12 år {Handelsnavn} er indiceret som monoterapi eller tillægsbehandling af epilepsi med partielle anfald og generaliserede anfald, herunder tonisk-kloniske anfald og anfald ved Lennox-Gastaut syndrom”. 
“Adults and children above 12 years {Tradename} is indicated for use as adjunctive or monotherapy in the treatment of epilepsy, for partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with Lennox-Gastaut Syndrome”.
• Hævelser i ansigtet (ødem) eller hævede kirtler på halsen, i armhulerne eller i lysken (lymfadenopati) 
• swelling around the face (oedema) or swollen glands in the neck, armpit or groin
De er påtrykt 'GS CL2' på den ene side og '5' på den anden side. 
They are marked ‘GS CL2' on one side; and ‘5' on the other.
• Hyppigere anfald hos patienter med epilepsi 
• in people who already have epilepsy, seizures happening more often
Dispergibel tablet / tyggetablet. 
Dispersible/chewable tablet.
Bipolar lidelse 
Bipolar disorder
Lamictal kan anvendes sammen med andre lægemidler til behandling af disse tilstande. 
• For children aged between 2 and 12 years, Lamictal can be used with other medicines, to treat those conditions.
Hjælpestof: Hver tablet indeholder 109,0 mg lactose. 
Excipient: Each tablet contains 109.0 mg lactose.
Hos patienter, som får samtidig behandling med valproat, skal der benyttes et hensigtsmæssigt behandlingsregimen (se pkt. 
In patients receiving concomitant therapy with valproate, the appropriate treatment regimen should be used (see section 4.2).
Hos patienter, som får samtidig behandling med lopinavir/ritonavir, skal der benyttes et hensigtsmæssigt behandlingsregimen (se pkt. 
In patients receiving concomitant therapy with lopinavir/ritonavir, the appropriate treatment regimen should be used (see section 4.2).
Hos patienter, som får samtidig behandling med rifampicin, skal der benyttes et hensigtsmæssigt behandlingsregimen (se pkt. 
In patients receiving concomitant therapy with rifampicin, the appropriate treatment regimen should be used (see section 4.2).
Litauen The Wellcome Foundation Limited Glaxo Wellcome House 
Lithuania The Wellcome Foundation Limited
Der blev dog observeret reduceret føtalvægt og forsinket forbening af skelettet ved eksponeringsniveauer under eller lig med den forventede kliniske eksponering. 
In reproductive and developmental toxicity studies in rodents and rabbits, no teratogenic effects but reduced foetal weight and retarded skeletal ossification were observed, at exposure levels below or similar to the expected clinical exposure.
Startpakning med 42 dispergible tabletter / tyggetabletter. 
Starter pack of 42 dispersible/chewable tablets.
Under kliniske forsøg med monoterapi: Ikke almindelig: 
During monotherapy clinical trials: Uncommon:
Hjælpestof: Hver tablet indeholder 46,9 mg lactose. 
Excipient: Each tablet contains 46.9 mg lactose.
“Børn på 2 til 12 år {Handelsnavn} er indiceret som tillægsbehandling af epilepsi med partielle anfald og generaliserede anfald, herunder tonisk-kloniske anfald og anfald ved Lennox-Gastaut syndrom”. 
“Children 2 to 12 years {Tradename} is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures including tonic-clonic seizures and the seizures associated with Lennox-Gastaut Syndrome”.
NAVN OG ADRESSE PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN [Se bilag I - udfyldes nationalt] 
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally]
200-400 mg/dag (fordelt på to doser) 
200 − 400 mg/day (two divided doses)
Almene symptomer og reaktioner på administrationsstedet Under kliniske forsøg vedrørende bipolar sygdom: Almindelig: 
General disorders and administration site conditions During bipolar disorder clinical trials: Common:
Lamictal kan anvendes alene eller sammen med andre lægemidler til behandling af epilepsi. 
• For adults and children aged 13 years and over, Lamictal can be used on its own or with other medicines, to treat epilepsy.
Hvid til offwhite, aflang, bikonveks tablet med solbærlugt påtrykt "GS CL2" på den ene side og "5" på den anden side. 
White to off-white, elongated, biconvex tablet with a blackcurrant odour, marked “GS CL2” on one side and “5” on the other.
Knogler, led, muskler og bindevæv Meget sjælden: 
Musculoskeletal and connective tissue disorders Very rare:
For at nå vedligeholdelsesdosis må doserne maksimalt øges med 0,3 mg/kg hver eller hver anden uge, indtil den optimale respons er opnået, og vedligeholdelsesdosis må maksimalt være 200 mg/dag 
To achieve maintenance, doses may be increased by maximum of 0.6 mg/kg every one to two weeks until optimal response is achieved, with a maximum of maintenance dose of 200 mg/day
Startpakning 42 dispergible tabletter / tyggetabletter, ikke-valproat tillægsbehandling 
Starter pack 42 dispersible/chewable tablets, non-valproate add-on therapy
De er påtrykt 'GS EC5' på den ene side og '200' på den anden side. 
They are marked ‘GSEC5' on one side; and ‘200' on the other.
25 mg tabletter: 
25 mg tablets:
De er påtrykt 'GS CL7' på den ene side og '100' på den anden side. 
They are marked ‘GSCL7' on one side; and ‘100' on the other.
Der er ikke enighed om, hvilket lægemiddel der bør anvendes som den indledende behandling. 
There is no consensus on which drug should be used as initial treatment; however, the data analysed do not exclude that lamotrigine could be the initial agent.
Af hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet eller skraldespanden. 
If you have any unwanted Lamictal tablets, don't dispose of them in your waste water or your household rubbish.
Pakninger med 30 dispergible tabletter / tyggetabletter. 
Packs of 30 dispersible/chewable tablets.
De er påtrykt 'GS CX7' på den ene side og '50' på den anden side. 
They are marked ‘GSCX7' on one side; and ‘50' on the other.
Sådan skal du tage Lamictal 
HOW TO TAKE LAMICTAL
Hver Lamictal 200 mg tablet indeholder 200 mg lamotrigin. 
Each Lamictal 200 mg tablet contains 200 mg lamotrigine.
Hjælpestof: Hver tablet indeholder 93,9 mg lactose. 
Excipient: Each tablet contains 93.9 mg lactose.
Lamictal kan også anvendes sammen med andet medicin til behandling af de anfald, der opstår i forbindelse med tilstanden Lennox-Gastautsyndrom, - Hos børn i alderen 2-12 år. 
Lamictal can also be used with other medicines to treat the seizures that occur with a condition called Lennox-Gastaut syndrome.
• Bupropion, der anvendes til behandling af psykiske problemer eller til rygeafvænning. 
• bupropion, used to treat mental health problems or to stop smoking Î Tell your doctor if you are taking any of these.
For at nå vedligeholdelsesdosis må doserne maksimalt øges med 25-50 mg hver eller hver anden uge, indtil den optimale respons er opnået 
To achieve maintenance, doses may be increased by maximum of 25 - 50 mg every one to two weeks until optimal response is achieved
(Startpakning 42 tabletter, monoterapi - kalender pakning viser dagnumre): 1 2 3 4 5 6 7 (en lomme) 
(Starter pack 42 tablets, monotherapy - calender pack showing day numbers): 1 2 3 4 5 6 7 (one pocket)
Dispergible tabletter / tyggetabletter: 
Dispersible/chewable tablets:
Hver pakning med blistere indeholder 30, 56 eller 100 tabletter. 
Each pack contains blisters of 30, 56 or 100 tablets.
25 mg Tabletter 
25 mg Tablet
Lægemidler, der signifikant hæmmer glukuronidering af lamotrigin 
Medicinal products that significantly inhibit glucuronidation of lamotrigine
200 mg/dag 300 mg/dag 400 mg/dag 
200 mg/day 300 mg/day 400 mg/day
Du skal dog være opmærksom på, at de kan være alvorlige. 
But you must be aware that they are potentially serious - so, if you notice any of these symptoms:
Lamictal 5 mg dispergible tabletter / tyggetabletter er aflange med buede sider. 
Lamictal 5 mg dispersible/chewable tablets are elongated with curved sides.
400 mg/dag 300 mg/dag 200 mg/dag 
400 mg/day 300 mg/day 200 mg/day
Hver Lamictal 100 mg tablet indeholder 100 mg lamotrigin. 
Each Lamictal 100 mg tablet contains 100 mg lamotrigine.
Pakninger med 30, 50, 56, 60, 90 eller 100 tabletter. 
Packs of 30, 50, 56, 60, 90 or 100 tablets.
Hver Lamictal 25 mg tablet indeholder 25 mg lamotrigin. 
Each Lamictal 25 mg tablet contains 25 mg lamotrigine.
Hver pakning med blistere indeholder 10, 14, 28, 30, 50 eller 56 tabletter. 
Each pack contains blisters of 10, 14, 28, 30, 50 or 56 tablets.
Dette dosisregimen skal følges, når andre lægemidler, der ikke signifikant hæmmer eller inducerer glukuronidering af lamotrigin, tilføjes 
This dosage regimen should be used when other medicinal products that do not significantly inhibit or induce lamotrigine glucuronidation are added
Pakninger med 14, 21, 30, 42, 50, 56 eller 100 tabletter. 
Packs of 14, 21, 30, 42, 50, 56 or 100 tablets.
Lamictal 100 mg tabletter er påtrykt 'GS SEE5' på den ene side og '100' på den anden side. 
Lamictal 100 mg tablets are marked ‘GSEE5' on one side and ‘100' on the other.
Lamictal 50 mg tabletter er påtrykt 'GS SEE1' på den ene side og '50' på den anden side. 
Lamictal 50 mg tablets are marked ‘GSEE1' on one side and ‘50' on the other.
Lamictal Dispersible 25mg Starter-Pack Mono 
Lamictal Dispersible 25mg Starter-Pack Mono 25 mg Dispersible Tablet
Lamictal 25 mg tabletter er påtrykt 'GS SEC7' på den ene side og '25' på den anden side. 
Lamictal 25 mg tablets are marked ‘GSEC7' on one side and ‘25' on the other.
Effekten kan ikke blive opretholdt hos alle børn, der tager lamotrigin for behandling af typiske absencer. 
In children taking lamotrigine for the treament of typical absence seizures, efficacy may not be maintained in all patients.
DET SKAL DU VIDE, FØR DU BEGYNDER AT TAGE LAMICTAL 
BEFORE YOU TAKE LAMICTAL
Tilføjelse af lægemidler, der IKKE signifikant hæmmer eller inducerer lamotrigin-glukuronideringen (se pkt. 
Addition of medicinal products that do NOT significantly inhibit or induce lamotrigine glucuronidation (see section 4.5):
5-15 mg/kg/dag (én gang dagligt eller fordelt på to doser) 
5 − 15 mg/kg/day (once a day or two divided doses)
200 mg Tabletter 
200 mg Tablet
100-200 mg/dag (én gang dagligt eller fordelt på to doser) 
100 − 200 mg/day (once a day or two divided doses)
Hver Lamictal 50 mg tablet indeholder 50 mg lamotrigin. 
Each Lamictal 50 mg tablet contains 50 mg lamotrigine.
42 dispergible tabletter / tyggetabletter 
42 dispersible/chewable tablets
Behandlingsregimen for lamotrigin tillægsbehandling uden valproat og uden induktorer af lamotrigin glukoronidation bør derfor anvendes hos patienter i samtidig behandling med oxcarbazepin (se pkt. 
Therefore in patients receiving concomitant therapy with oxcarbazepine, the treatment regimen for lamotrigine adjunctive therapy without valproate and without inducers of lamotrigine glucuronidation should be used (see section 4.2).
Uge 3 og frem 
Week 2 Week 3 onwards
1,2 mg/kg/dag (fordelt på to doser) 
1.2 mg/kg/day (two divided doses)
150 mg/dag 225 mg/dag 300 mg/dag 
150 mg/day 225 mg/day 300 mg/day
For at nå vedligeholdelsesdosis må doserne maksimalt øges med 100 mg hver eller hver anden uge, indtil den optimale respons er opnået 
To achieve maintenance, doses may be increased by maximum of 100 mg every one to two weeks until optimal response is achieved
Pakninger med 10, 14, 28, 30, 50 eller 56 dispergible tabletter / tyggetabletter. 
Packs of 10, 14, 28, 30, 50 or 56 dispersible/chewable tablets.
Holland GlaxoSmithKline BV Huis ter Heideweg 62 
GlaxoSmithKline BV Huis ter Heideweg 62 3705 LZ Zeist The Netherlands
Finland GlaxoSmithKline Oy Piispansilta 9 A 
GlaxoSmithKline Oy Piispansilta 9 A 02230 Espoo Finland
400 mg/dag 
400 mg/day
Tillægsbehandling UDEN valproat og UDEN induktorer af lamotrigin-glukuronidering (se pkt. 
Adjunctive therapy WITHOUT valproate and WITHOUT inducers of lamotrigine glucuronidation (see section 4.5):
50 mg Tabletter 
50 mg Tablet
Dette dosisregimen skal kombineres med andre lægemidler, der ikke signifikant hæmmer eller inducerer glukuronidering af lamotrigin 
This dosage regimen should be used with other medicinal products that do not significantly inhibit or induce lamotrigine glucuronidation
Dette dosisregimen skal følges, når andre lægemidler, der ikke signifikant hæmmer eller inducerer glukuronidering af lamotrigin, seponeres 
This dosage regimen should be used when other medicinal products that do not significantly inhibit or induce lamotrigine glucuronidation are withdrawn
Knogler, led, muskler og bindevæv Under kliniske forsøg vedrørende bipolar sygdom: Almindelig: 
Musculoskeletal and connective tissue disorders During bipolar disorder clinical trials: Common:
Ataksi. 
ataxia.
200 mg/dag 150 mg/dag 100 mg/dag 
200 mg/day 150 mg/day 100 mg/day
Diplopi, tågesyn. 
diplopia, blurred vision.
Tillægsbehandling UDEN valproat og MED induktorer af lamotrigin-glukuronidering (se pkt. 
Adjunctive therapy WITHOUT valproate and WITH inducers of lamotrigine glucuronidation (see section 4.5):
0,6 mg/kg/dag (fordelt på to doser) 
0.6 mg/kg/day (two divided doses)
• Hududslæt eller rødme 
• skin rashes or redness
200 mg/dag 
200 mg/day
100 mg Tabletter 
100 mg Tablet
I undersøgelser, der havde til formål at vurdere lægemidlers effekt på centralnervesystemet, afveg de opnåede resultater ved brug af doser på 240 mg lamotrigin administreret til raske frivillige ikke fra de opnåede resultater ved brug af placebo. 
In tests designed to evaluate the central nervous system effects of medicinal products, the results obtained using doses of 240 mg lamotrigine administered to healthy volunteers did not differ from placebo, whereas both 1000 mg phenytoin and 10 mg diazepam each significantly impaired fine visual motor co-ordination and eye movements, increased body sway and produced subjective sedative effects.
300 mg/dag 225 mg/dag 150 mg/dag 
300 mg/day 225 mg/day 150 mg/day
Lamictal Dispersible 50mg Starter-Pack add-on 
Lamictal Dispersible 50mg Starter-Pack add-on 50 mg Dispersible Tablet
Pakninger med 10, 14, 21, 28, 30, 42, 50, 56 eller 60 dispergible tabletter / tyggetabletter. 
Packs of 10, 14, 21, 28, 30, 42, 50, 56 or 60 dispersible/chewable tablets.
28 dispergible tabletter / tyggetabletter 
28 dispersible/chewable tablets
Pakninger med 14, 30, 42, 56, 90 eller 100 tabletter. 
Packs of 14, 30, 42, 56, 90 or 100 tablets.
100 mg/dag 150 mg/dag 200 mg/dag 
100 mg/day 150 mg/day 200 mg/day
Pakninger med 10, 30, 50, 56, 60, 90, 100 eller 200 dispergible tabletter / tyggetabletter. 
Packs of 10, 30, 50, 56, 60, 90, 100 or 200 dispersible/chewable tablets.
4.5) afhængigt af den oprindelige dosis lamotrigin: 
Withdrawal of inducers of lamotrigine glucuronidation (see section 4.5), depending on original dose of lamotrigine:
Hver pakning med blistere indeholder 10, 14, 21, 28, 30, 42, 50, 56 eller 60 tabletter. 
Each pack contains blisters of 10, 14, 21, 28, 30, 42, 50, 56 or 60 tablets.
300 mg/dag 
300 mg/day
100 mg/dag (fordelt på to doser) 
100 mg/day (two divided doses)
200 dispergible tabletter / tyggetabletter 
200 dispersible/chewable tablets
Indehaver af markedsføringstilladelsen: [Se bilag I - udfyldes nationalt] 
Marketing Authorisation Holder: [See Annex I - To be completed nationally]
Seponering af lægemidler, der IKKE signifikant hæmmer eller inducerer glukuronidering af lamotrigin (se pkt. 
Withdrawal of medicinal products that do NOT significantly inhibit or induce lamotrigine glucuronidation (see section 4.5):